Allergan reported a GAAP operating loss of $467 million, or $1.39 per share, in the second quarter of 2018 and a non-GAAP operating income of $1.97 billion, or $4.42 per share, an increase of 4.6% from 2017’s second quarter, according to a press release.
Net revenues were $4.124 billion compared with $4.007 billion a year ago.
The company’s total GAAP operating expenses decreased 14.9% to $1.19 billion for the quarter, while its non-GAAP expenses decreased from $1.22 billion in 2017’s second quarter to $1.13 billion. GAAP research and development costs (Read more...)
Uncategorized